ClinicalTrials.gg
RecruitingNCT07276997Updated Jun 15, 2026

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

A Phase 2 interventional study of Icalcaprant and Placebo for Icalcaprant in Major Depressive Disorder, sponsored by AbbVie. Recruiting at 33 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 53 studies in Depressive Disorder, Major by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · AbbVie.

Planned enrollment
40th of 53
195 · median 442
Started
2025
the only one that year
Phase 2
12 of 53
1 open now
Registered
53rd of 53
by date

Among the 53 studies in Depressive Disorder, Major by AbbVie, this one is the 40th largest by planned enrollment, is the only one that started in 2025, is one of 12 in phase 2, and was the 53rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 53 studies in Depressive Disorder, Major by AbbVie is open now, in 1 country.

By country, each count listing its studies:

Who these studies take

Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Depressive Disorder, Major by AbbVie, or all of them as a file.
02

Study summary

Major depressive disorder (MDD; depression) is a mood disorder that causes a continued feeling of sadness and loss of interest. It is a common and serious illness that can cause both emotional and physical symptoms such as feelings of sadness, irritability, not being able to focus on activities, tiredness, changes in eating habits, and aches and pains. This study will assess the changes in disease activity and adverse events of oral Icalcaprant in adult participants with major depressive disorder who are currently experiencing a major depressive episode (MDE).

Icalcaprant is an investigational drug being developed for the treatment of depressive episodes in adult participants with major depressive disorder. Participants are placed in 1 of 3 groups, called treatment arms. There is a 1 in 3 chance that a participant will be assigned to placebo treatment. Around 195 adult participant with major depressive disorder will be enrolled in approximately 35 sites in North America.

Participants will receive oral capsules of Icalcaprant or matching placebo once daily for 6 weeks, with a 30-day safety follow-up.

There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • Icalcaprant
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with a diagnosis of major depressive disorder (MDD) according to the , fifth edition, text revision (DSM-5-TR) without psychotic features, confirmed by the Mini International Neuropsychiatric Interview (MINI) 7.0.
  • (BMI) is ≥ 18.0 to ≤ 35.0 kg/m\^2
  • Currently experiencing an major depressive episode (MDE) beginning at least 4 weeks prior to consent and not exceeding 6 months prior to Screening
  • Normal physical examination findings, clinical laboratory test results, vital signs, and 12-lead results at Visit 1 or abnormal results that are judged not by the investigator and documented as such in the eCRF.

Exclusion criteria

Exclusion Criteria:

  • Has failed (no more than 25% response on Antidepressant Treatment History Questionnaire (ATRQ)) 3 or more antidepressant treatments during the current depressive episode despite an adequate dose (per ATRQ) and duration (at least 6 weeks).
  • History of an allergic reaction or significant sensitivity to constituents of the study drug (and its ) and/or other products in the same class.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
195 participants (estimated)

Study arms

  • Experimental
    Icalcaprant Dose A

    Participants will receive oral Icalcaprant dose A once daily for 6 weeks and attend a follow up visit 30 days following end of treatment.

    Drug: Icalcaprant

  • Experimental
    Icalcaprant Dose B

    Participants will receive oral Icalcaprant dose B once daily for 6 weeks and attend a follow up visit 30 days following end of treatment.

    Drug: Icalcaprant

  • Placebo comparator
    Placebo for Icalcaprant

    Participants will receive oral placebo once daily for 6 weeks and attend a follow up visit 30 days following end of treatment.

    Drug: Placebo for Icalcaprant

Interventions

  • Oral Capsules

  • DrugPlacebo for Icalcaprant

    Oral Capsules

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score.

    Montgomery-Åsberg Depression Rating Scale (MADRS) The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are to be rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item will be scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity.

    Time frame: Up to approximately 6 weeks

  2. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.

    Time frame: Up to approximately 10 weeks

Secondary outcomes

  1. Change from Baseline in Clinical Global Impression (CGIS)

    Change from Baseline in Clinical Global Impression (CGIS)-The CGIS is a single-item clinician-reported measure of severity of depression. Clinicians are asked to consider their total clinical experience with Participants with major depressive disorder (MDD) and assess how severely ill the participant has been during the past 7 days. Response options range from 1 to 7: 1 = normal to 7 = very severely ill.

    Time frame: Up to approximately 6 weeks

07

Study locations

33 of 33 sites recruiting
  • Harmonex /ID# 277517
    Dothan, Alabama 36303, United States
    Recruiting
  • Ima Clinical Research Phoenix (Alea) /ID# 277516
    Phoenix, Arizona 85012, United States
    Recruiting
  • Preferred Research Partners /ID# 279206
    Little Rock, Arkansas 72211, United States
    Recruiting
  • Woodland International Research Group /ID# 277605
    Little Rock, Arkansas 72211, United States
    Recruiting
  • Advanced Research Center /ID# 277537
    Anaheim, California 92805, United States
    Recruiting
  • Sun Valley Research Center /ID# 277513
    Imperial, California 92251, United States
    Recruiting
  • Synergy San Diego /ID# 277553
    Lemon Grove, California 91945, United States
    Recruiting
  • Accellacare - Long Beach /ID# 279181
    Long Beach, California 90807, United States
    Recruiting
  • CenExel CNR /ID# 277533
    Sherman Oaks, California 91403, United States
    Recruiting
  • Inland Psychiatric Medical Group /ID# 279275
    Temecula, California 92591, United States
    Recruiting
  • Sunwise Clinical Research /ID# 277555
    Walnut Creek, California 94596, United States
    Recruiting
  • CenExel Hollywood FL /ID# 278200
    Hollywood, Florida 33024, United States
    Recruiting
  • Cns Healthcare - Jacksonville /ID# 277658
    Jacksonville, Florida 32256, United States
    Recruiting
  • GMI Florida - Central Miami Medical Institute /ID# 278218
    Miami, Florida 33125, United States
    Recruiting
  • Clinical Neuroscience Solutions - Orlando - East South Street /ID# 277558
    Orlando, Florida 32801, United States
    Recruiting
  • EquiPath Health & Research Tampa Bay, LLC /ID# 279128
    Riverview, Florida 33578, United States
    Recruiting
  • Trialmed /ID# 277601
    Atlanta, Georgia 30328, United States
    Recruiting
  • Evergreen Clinical Trials - Norcross /ID# 279421
    Norcross, Georgia 30092, United States
    Recruiting
  • Flourish Research - Great Lakes Clinical Trials /ID# 278201
    Chicago, Illinois 60640, United States
    Recruiting
  • Amr Conventions Research /ID# 277547
    Warrenville, Illinois 60555, United States
    Recruiting
  • Redbird Research /ID# 277485
    Las Vegas, Nevada 89119, United States
    Recruiting
  • Ima Clinical Research - Manhattan /ID# 278212
    New York, New York 10036, United States
    Recruiting
  • Manhattan Behavioral Medicine /ID# 277910
    New York, New York 10036, United States
    Recruiting
  • Quest Therapeutics of Avon /ID# 277550
    Avon Lake, Ohio 44012-1004, United States
    Recruiting
  • OSU Psychiatry Department /ID# 277529
    Columbus, Ohio 43210-1250, United States
    Recruiting
  • Sooner Clinical Research /ID# 277659
    Oklahoma City, Oklahoma 73116, United States
    Recruiting
  • Clinical Neuroscience Solutions /ID# 278192
    Memphis, Tennessee 38119, United States
    Recruiting
  • Austin Clinical Trial Partners /ID# 279321
    Austin, Texas 78737, United States
    Recruiting
  • Community Clinical Research - Cross Park Drive /ID# 277935
    Austin, Texas 78754, United States
    Recruiting
  • Houston Clinical Trials - Bellaire /ID# 277551
    Bellaire, Texas 77401, United States
    Recruiting
  • Pillar Clinical Research - Richardson /ID# 276764
    Richardson, Texas 75080, United States
    Recruiting
  • Northwest Clinical Research Center /ID# 277484
    Bellevue, Washington 98007, United States
    Recruiting
  • Core Clinical Research /ID# 277518
    Everett, Washington 98201, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2027, 21 months after the start.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's planned 21 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Dec 11, 2025
StartActual
Dec 18, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07276997
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Dec 11, 2025
Start date
Dec 18, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jun 15, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icalcaprant

Start the discussion